-
2022 SABCS East Wind is Coming Today, Green Lake Up the Mountain - New Dynamics of CDK4/6 Inhibitors in HR+/HER2-Breast Cancer
Time of Update: 2022-12-30
Featured Study IV (P5-02-02)Relationship between ER+/HER2-metastatic breast cancer genome mapping and previous CDK4/6i treatmentTo understand the molecular processes driving CDK4/6i resistance, the researchers genetically tested 1,853 patients with ER+/HR2 advanced breast cancer and found that patients who had previously received treatment showed significant ESR1 mutation rates in solid tissue and liquid biopsies compared with patients who did not receive CDK4/6i.
-
Scientists used new techniques to trace the process from smell to brain
Time of Update: 2022-11-04
”High-throughput sequencing of single neuron projections reveals spatial organization in the olfactory cortex Using the brain-localization technique BARseq, the researchers studied hundreds of neurons in the mouse olfactory bulb at once.
-
Global Chief Marketing Officer event for the first time in the food industry
Time of Update: 2022-09-01
The only national legal representative of the World Federation of Advertisers, the China Advertisers Association, and the China Food News Agency launched the "2022 Global Chief Marketing Officer (China) Food Industry Candidates" selection activity, the purpose is to let these companies participate and take action, Bringing their brand to the world is of great significance for establishing a "big food concept" and strengthening the food industry .
-
Professor Hu Jie: Treatment of advanced NSCLC - PD-(L)1 is the cornerstone K drug is the best choice
Time of Update: 2022-02-20
➤ At the 2021 World Conference on Lung Cancer (WCLC), Professor Cheng Ying of Jilin Cancer Hospital, as the lead PI of the KEYNOTE-407 China extension study, reported the final analysis results of the study: Among the 125 patients enrolled, drug K The combination therapy group showed a sustained OS benefit, with a 2-year OS rate of 56.
-
Tasly's subsidiary bezafibrate sustained-release tablets and temozolomide for injection obtained drug registration certificates
Time of Update: 2021-11-04
On October 21, Tasly issued an announcement stating that its subsidiaries, bezafibrate sustained-release tablets and temozolomide for injection, have obtained drug registration certificates .
Sustained-release bezafibrate tablets are used to treat adult hypertriglyceridemia and mixed hyperlipidemia .
-
Are you aware of these problems in the clinical application of macrolides
Time of Update: 2021-04-20
Generally speaking, macrolide drugs are a group of relatively safe antibiotics, but due to their adverse reactions and interactions with other drugs, there are certain relative contraindications in clinical application.
In clinical application of macrolide drugs, factors that need to be considered include dosage, route of administration, and treatment goals.
-
Novel coronavirus pneumonia: advantages and disadvantages of recognizing antibodies
Time of Update: 2020-02-15
The infection of novel coronavirus caused more than 60 thousand cases of infectious pneumonia, and thousands of patients lost their lives No matter the government departments, scientific research team
-
[perspective] from 1949 to 2017, "malignant lymphoma" has 41 therapeutic drugs in the world
Time of Update: 2018-12-19
Malignant lymphoma is one of the ten most common cancers in China According to the data published in the annual report of China Cancer Registry, the incidence rate of malignant lymphoma is about 5/10
